Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NNVC - features
NNVC - 11/13/2023 catalysts
$NNVC
__________________
NV-387 IS HIGHLY ACTIVE AGAINST TESTED CORONAVIRUSES INCLUDING SARS-COV-2 IN PRE-CLINICAL STUDIES
THE ENTIRE FLOAT ON NNVC IS JUST 11.2 MILL ACCORDING TO FINVIZ!
******NanoViricides, Inc. is possibly one of the few laboratories in the world to have developed an orally effective nanomedicine.
_________________________________
$NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** NNVC
NNVC - 11/13/2023 catalysts
$NNVC
__________________VIRAL THERAPEUTICS_______________
NOTEWORTHY CATALYSTS
1. Broad-Spectrum, Pan-Coronavirus Drug NV-CoV-2 (API NV-387) for COVID, certain cases of long COVID, Seasonal Coronaviruses, MERS is in Clinical Trials. Two formulaJons are in clinical trials at present: Oral Syrup which can be titrated for body weight and is therefore preferable in pediatric seeng, and Oral Gummies, a fixed strength dosage form generally preferable for adults. We believe they would be highly effecJve for mild-to-moderate (non-hospitalized) cases of COVID. AddiJonally, NV-CoV-2 Solu=on for Injec=on, Infusion, and Inhala=on is developed for hospitalized COVID patients with severe disease; direct lung inhalaJon should provide significantly superior benefits by providing high pulmonary local concentration of the drug. NV-CoV-2 (NV-387) was found to have strong effectiveness in mulJple coronaviruses in vitro, and also strong effectiveness even when compared to remdesivir in animal studies of lethal lung infecJon. We believe the human clinical trial results should be consistent with these pre-clinical studies, and if so, would establish NV-CoV-2 as perhaps the most effecJve COVID treatment. There is no safe and effecJve COVID drug that covers all the paJent populaJons and disease severiJes at present, indicating significant unmet medical needs.
2. NV-387 Expanded Indications Program. We are elucidating the breadth of the anJviral spectrum of NV-387 at present. NV-387 is based on mimicking sulfated proteoglycans to a_ack the virus parJcle. A large number of viruses bind to such structures before gaining cell entry, including RSV, human MetaPneumoVirus (hMPV), certain Adenoviruses, other respiratory pathogens, as well as a number of systemic viruses such as Dengue viruses, Chickengunya, among others. Successful addiJonal indicaJons against any such viruses, if any, would significantly improve the return on investment, while fulfilling unmet medical needs.
3. Such additional indications would be eligible for Phase II/III studies with NV-387 having completed Phase I studies already.
4. Additonally, NV-387-R Could Result in Potential Cure Against a Number of Non-Latency Viruses.
HerpeCideTM Program. Variants of NV-HHV-101 are expected to become clinical drug candidates for topical treatment of HSV-2 “genital ulcers”, and HSV-1 “cold sores” soon aqer NV-HHV-101 goes into clinical studies. NV-HHV-101 is anJcipated to further expand into additional indications against chickenpox – a possibly orphan drug in the USA – and PHN (a morbidity of shingles persistent pain that may last for six months or longer, aqer the rash resolves).
We are also developing drugs against HIV.
******NanoViricides, Inc. is possibly the first in the world to have developed an orally effective nanomedicine.
_________________________________
$NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** NNVC
$NNVC - 11/13/2023 update
$NNVC
_____________________________
NEW ERA IN TARGETED ANTI-VIRAL THERAPEUTICS
NanoViricides, Inc. is a globally leading company in the application of nanomedicine technologies to the complex issues of viral diseases. The nanoviricide® technology enables direct attacks at multiple points on a virus particle. It is believed that such attacks would lead to the virus particle becoming ineffective at infecting cells. Antibodies in contrast attack a virus particle at only a maximum of two attachment points per antibody. In addition, the nanoviricide technology also simultaneously enables attacking the rapid intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The nanoviricide technology is the only technology in the world, to the best of our knowledge, that is capable of both (a) attacking extracellular virus, thereby breaking the reinfection cycle, and simultaneously (b) disrupting intracellular production of the virus, thereby enabling complete control of a virus infection.
_________________________________
$NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** NNVC
EEENF - funding
How to finance the new Africa venture? Why, just the usual way.
By issuing 322,147,513 new shares to water down our share price. (When they say 'fully paid' ordinary shares, they mean fully paid by us.)
__________________________________________
Announcement Summary
Entity name
88 ENERGY LIMITED
Announcement Type
New announcement
Date of this announcement
13/11/2023
The Proposed issue is:
Total number of +securities proposed to be issued for a placement or other type of issue
ASX +security code +Security description
Maximum Number of
+securities to be issued
88E ORDINARY FULLY PAID 322,147,513
Proposed +issue date
17/11/2023
source: https://wcsecure.weblink.com.au/pdf/88E/02739245.pdf
___________________________________________________________
Announcement --- Namibia farm-in
From: ASX
re: $EEENF
________________________________________________
ABN 80 072 964 179
This announcement contains inside information
88 Energy Limited
NAMIBIAN OIL AND GAS FARM-IN AGREEMENT
88 Energy Limited (ASX:88E, AIM:88E, OTC:EEENF) (88 Energy or the Company) is pleased to
announce the execution of a three stage farm-in agreement (Farm-In Agreement) with a wholly-owned
subsidiary of Monitor Exploration Limited (Monitor) to earn up to a 45% non-operated working interest
in onshore Petroleum Exploration Licence 93 (PEL 93), located in the Owambo Basin, Republic of
Namibia (Namibia).
Farm-In Agreement Highlights
• Farm-In Agreement provides a staged entry into PEL 93, a vast 18,500km2 onshore acreage
position comprising blocks 1717 and 1817 in the Owambo Basin, Namibia (the Licence).
• Namibia represents one of the last frontier oil and gas jurisdictions capable of delivering multi-billion
barrel discoveries, as evidenced by the recent Venus-1X offshore light oil discovery.
• Exposure to a first-class operating jurisdiction, with a highly competitive petroleum regime.
• Farm-In Agreement provides an opportunity to earn a significant working interest with future
potential to transition to project operator.
• Farm-in to PEL 93 and forward work-program complementary to 88E’s existing Alaskan exploration
and appraisal activities.
• Partner and operator, Monitor, has deep technical experience with extensive in-country and
regional knowledge.
• The Licence includes an extensive lead portfolio, with ten significant independent structural
closures identified from a range of geophysical and geochemical techniques. Considerable
potential for more leads to be identified as dataset is expanded.
• Pathway to potential commercialisation with logical staged work-program.
• Forward program to include acquisition of ~200 line-kilometres of low-impact 2D seismic planned
for mid-2024 and potential initial exploration well targeting the Damara play as early as H2 CY2025.
• Farm-in Agreement remains subject to Namibian government and other regulatory approvals,
which are expected to be received by Q1 2024.
88 Energy Managing Director, Ashley Gilbert, commented:
“The execution of this farm-in agreement with Monitor provides 88 Energy and its shareholders with a
fantastic opportunity to earn a significant working interest in a very large scale, highly prospective,
under-explored acreage position on attractive and logically staged commercial terms.
source: https://wcsecure.weblink.com.au/pdf/88E/02739242.pdf?bcsi_scan_b9c1724afa447587=rp7DDFzhQSa2owrR4ZesFYaGIdQPAAAABgQQbg==&bcsi_scan_filename=02739242.pdf
__________________________________________________________________________________
__________________________________________________________________________________
EEENF trading halt
___________________________________________________________________
Market Announcement 11/13/2023
13 November 2023
13 November 2023 Market Announcement 1/1
ASX Limited ASX Customer Service Centre 131 279 | asx.com.au
#10655684v1
88 Energy Limited (ASX: 88E) – Trading Halt
Description
The securities of 88 Energy Limited (‘88E’) will be placed in trading halt at the request of 88E, pending it
releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the
earlier of the commencement of normal trading on Wednesday, 15 November 2023 or when the
announcement is released to the market. source: https://wcsecure.weblink.com.au/pdf/88E/02738869.pdf
Issued by
Nicholas Mountain
Adviser, Listings Compliance
Xalles recluse CEO
$XALL
__________________________________
Agreed, like a tortoise, mostly withdrawn into his shell, yet you never know
when he'll suddenly materialize and shock investors with a 3 Billion share addition
to the O/S. Such is his power. The Amazing Kreskin has nothing on this quixotic, pink-sheet figure of mystery.
Powers that mystify even himself.
_______________________________________
$XALL
NMTC - Technical opinion
$NMTC ****
___________________________________
INDICATOR:
Composite Indicator
Trend Seeker®
BUY
Short Term Indicators
20 Day Moving Average
BUY
20 - 50 Day MACD Oscillator
BUY
20 - 100 Day MACD Oscillator
SELL
20 - 200 Day MACD Oscillator
SELL
20 - Day Average Volume: 201,310 Average: HOLD
source: BarChart.COM --- https://www.barchart.com/stocks/quotes/NMTC/opinion11/08/2023
____________________________
$NMTC *** NMTC *** NMTC *** NMTC *** NMTC *** NMTC ***
$NMTC - PR 11/07/2023
$NMTC
__________________________________________________
Projection -
Potential to penetrate large disease populations including epilepsy, Parkinson’s disease, and spinal cord stimulation, with total addressable markets of $1+ billion, $5+ billion, and $10+ billion, respectively.
Multi-billion market opportunity for combination devices; potential for technology adaptation and entry into AI and machine learning markets.
Platform technology with licensing potential for applications in urinary incontinence, pain management, hypertension, depression, and other related neurological disorders.
Ample capital resources to support upcoming commercial and development catalysts including the commercial launch of the Evo sEEG diagnostic line, and further development of OneRF and a thin-film-based SCS electrode system.
Leadership with deep expertise in medical device technology, marketing, and business development; world-class board of directors; esteemed scientific and physician advisory boards.
____________________________________________________
$NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC. *** $NMTC *** $NMTC *** $NMTC
8K Out - filed 11/07/2023
$NMTC
_______________________________
discussion:
Dave Rosa, CEO of NeuroOne, commented, “We remain bullish on the potential for this technology to cause a paradigm shift in how patients are treated in ablation procedures. The potential to reduce hospital stays, additional procedures, complications and cost gives us confidence that this will have a meaningful impact in the market. We hope to complete discussions with the FDA in the near future as we prepare for a targeted commercial launch in the first half of 2024.”[/I]
___________________________________
Current:
Float: 7,976,291 shares available to trade
_______________________________
$NMTC *** $NMTC *** $NMTC *** $NMTC *** NMTC *** NMTC ***
***News out NMTC
$NMTC - news out FDA response
_news today_____________________________
NeuroOne® Provides Progress Update on FDA 510(k) Submission for OneRF™ Ablation System
November 07 2023 - 08:00AM
GlobeNewswire Inc.
_____________________________
Current shares -
Float: 7,976,291 shares available to trade
_______________________________
$NMTC *** $NMTC *** $NMTC *** $NMTC *** NMTC. *** NMTC
$NMTC - up 5% from bottom
$NMTC - feature
$NMTC - MACD rising above 9D-MA
_____________________
Total shares outstanding ****** 23,919,184 (11/03/2023)
$NMTC
NeuroOne® Announces First Clinical Case Using Evo® sEEG Electrode in Robotic #Neurosurgery: Evo sEEG electrode used with Zimmer Biomet’s ROSA One® Brain during procedure at @ClevelandClinic.
Read here: https://t.co/5hLL0U97Od$NMTC #N1MTC pic.twitter.com/Rj21O8388A
— NeuroOne Medical Technologies Corporation (@N1MTC) May 17, 2023
--- Full Profile Here: https://insiderfinancial.com/newalert
[Operating cash burn reduction expected with the completion of development of the OneRF™ Ablation System beginning in Fiscal Q4 2023].
__________________________________________________
$NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC
$NMTC - feature
$NMTC - accumulation
_____________________
current float: ****** 7,976,291 (11/03/2023)
$NMTC
Full Profile Here: https://insiderfinancial.com/newalert
[Operating cash burn reduction expected with the completion of development of the OneRF™ Ablation System beginning in Fiscal Q4 2023].
__________________________________________________
$NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC
$NMTC - re 'Going Higher'
_____________________
$NMTC
STRATEGIC PARTNERSHIP WITH ZIMMER BIOMET (NYSE:ZBH, ~$27B MKT CAP) TO EXCLUSIVELY COMMERCIALIZE AND DISTRIBUTE EVO® DIAGNOSTIC ELECTRODES; ACCELERATED PAYMENT OF $3.5 MILLION RECEIVED IN AUGUST 2022
Operating cash burn reduction expected with the completion of development of the OneRF™ Ablation System beginning in Fiscal Q4 2023.
__________________________________________________
$NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC
NMTC - catalysts
$NMTC
_______________________________
Financial Highlights:
Product revenue of $630,000 in Q3 2023, compared to $32,000 in Q3 2022
Collaboration revenue of $1.46 million in first nine months of FY 2023, compared to $6,000 in first nine months of FY 2022
Operating cash burn reduction expected with the completion of development of the OneRF™ Ablation System beginning in Fiscal Q4 2023
Evo® sEEG:
Completed limited launch at target centers by end of July; full launch with Zimmer Biomet expected by end of fiscal fourth quarter
Positive user feedback received on product evaluation forms
Initiation of new sites expected to ramp in fiscal fourth quarter
Received first order for calendar 2024 product supply from Zimmer Biomet
OneRF™Ablation:
Submitted 510(k) to FDA on June 8th
Poster presentation on OneRF Ablation System preclinical study at the Neurological Disorders Summit (NDS 2023) in Italy
Received feedback from FDA regarding 510(k) submission for OneRF Ablation System
Spinal Cord Stimulation Program:
Completed 28 day animal implants of the Company’s thin film spinal cord stimulation paddle electrodes without any adverse events or neurological complications
Filed a non-provisional patent for a novel conformable thin film paddle lead for spinal cord placement
Drug Delivery Program:
Successfully completed proof of concept testing of drug delivery into the brain in a small animal model at the Mayo Clinic in Rochester, Minnesota
OTHER CATALYSTS
Disruptive next-generation diagnostic electrodes advancing a new era in neuroscience; foundational technology initially developed in collaboration with Mayo Clinic, a shareholder of the Company.
Strategic partnership with Zimmer Biomet (NYSE:ZBH, ~$27B mkt cap) to exclusively commercialize and distribute EVO® diagnostic electrodes; accelerated payment of $3.5 million received in August 2022.
Potential to penetrate large disease populations including epilepsy, Parkinson’s disease, and spinal cord stimulation, with total addressable markets of $1+ billion, $5+ billion, and $10+ billion, respectively.
Multi-billion market opportunity for combination devices; potential for technology adaptation and entry into AI and machine learning markets.
Platform technology with licensing potential for applications in urinary incontinence, pain management, hypertension, depression, and other related neurological disorders.
Ample capital resources to support upcoming commercial and development catalysts including the commercial launch of the Evo sEEG diagnostic line, and further development of OneRF and a thin-film-based SCS electrode system.
Leadership with deep expertise in medical device technology, marketing, and business development; world-class board of directors; esteemed scientific and physician advisory boards.
______________________________________________________________________________________
$NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC
NMTC - Debt to equity
$NMTC
_______________________________
Current: debt/equity: 0.31
Total Assets: *** $5,758,124 - per latest 10K (08/14/2023)
Total Liabilities * $1,836,826 - " - " - " - " - " - (08/14/2023)
https://www.otcmarkets.com/stock/NMTC/disclosure
_______________________________
$NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC
NMTC - low floater - structure
$NMTC
_______________________________
Current:
Float: 7,976,291 shares available to trade
_______________________________
$NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC
NMTC - low floater - structure
$NMTC
_______________________________
Current:
Float: 7,976,291 shares available to trade
_______________________________
$NMTC *** $NMTC *** $NMTC *** $NMTC ***
NMTC share structure
$NMTC
_______________________________
Current:
Held at DTC: 13,732,171 shares
_______________________________
$NMTC *** $NMTC *** $NMTC *** $NMTC ***
NMTC share structure
NMTC
_______________________________
current:
O/S: 23,919,184 shares
_______________________________
$NMTC *** $NMTC *** $NMTC *** $NMTC
NMTC partnership
___________________________
Highlights:
-- STRATEGIC PARTNERSHIP WITH ZIMMER BIOMET (NYSE:ZBH, ~$27B MKT CAP) TO EXCLUSIVELY COMMERCIALIZE AND DISTRIBUTE EVO® DIAGNOSTIC ELECTRODES; ACCELERATED PAYMENT OF $3.5 MILLION RECEIVED IN AUGUST 2022
-- NMTC HAS NO DEBT OUTSTANDING AS OF JUNE 30, 2023
-- PRODUCT REVENUE OF $630,000 IN Q3 2023, COMPARED TO $32,000 IN Q3 2022
_______________________________________________________________________________
$NMTC *** NMTC *** NMTC *** NMTC *** NMTC *** NMTC
NMTC ratings
NMTC
________________________________
Barchart Opinion
INDICATOR
Opinion Strength & Direction ***BUY
Composite Indicator
Trend Seeker® ***BUY
_________________________
Short Term Indicators
20 Day Moving Average ***BUY
_________________________________________
_______________________________________________________________________________
$NMTC *** NMTC *** NMTC *** NMTC *** NMTC *** NMTC
$NMTC treats
_______________
NMTC
_______________________________
Financial Highlights
Product revenue of $630,000 in Q3 2023, compared to $32,000 in Q3 2022
Collaboration revenue of $1.46 million in first nine months of FY 2023, compared to $6,000 in first nine months of FY 2022
Operating cash burn reduction expected with the completion of development of the OneRF™ Ablation System beginning in Fiscal Q4 2023
Evo® sEEG:
Completed limited launch at target centers by end of July; full launch with Zimmer Biomet expected by end of fiscal fourth quarter
Positive user feedback received on product evaluation forms
Initiation of new sites expected to ramp in fiscal fourth quarter
Received first order for calendar 2024 product supply from Zimmer Biomet
OneRF™Ablation:
Submitted 510(k) to FDA on June 8th
Poster presentation on OneRF Ablation System preclinical study at the Neurological Disorders Summit (NDS 2023) in Italy
Received feedback from FDA regarding 510(k) submission for OneRF Ablation System
Spinal Cord Stimulation Program:
Completed 28 day animal implants of the Company’s thin film spinal cord stimulation paddle electrodes without any adverse events or neurological complications
Filed a non-provisional patent for a novel conformable thin film paddle lead for spinal cord placement
Drug Delivery Program:
Successfully completed proof of concept testing of drug delivery into the brain in a small animal model at the Mayo Clinic in Rochester, Minnesota
_______________________________________________________________________________
$NMTC *** NMTC *** NMTC *** NMTC *** NMTC *** NMTC
NMTC partnership
___________________________
Highlights:
-- STRATEGIC PARTNERSHIP WITH ZIMMER BIOMET (NYSE:ZBH, ~$27B MKT CAP) TO EXCLUSIVELY COMMERCIALIZE AND DISTRIBUTE EVO® DIAGNOSTIC ELECTRODES; ACCELERATED PAYMENT OF $3.5 MILLION RECEIVED IN AUGUST 2022
-- NMTC HAS NO DEBT OUTSTANDING AS OF JUNE 30, 2023
-- PRODUCT REVENUE OF $630,000 IN Q3 2023, COMPARED TO $32,000 IN Q3 2022
_______________________________________________________________________________
$NMTC *** NMTC *** NMTC *** NMTC *** NMTC *** NMTC
NMTC news ....
$NMTC
___________________________
CATALYSTS:
1. Disruptive next-generation diagnostic electrodes advancing a new era in neuroscience; foundational technology initially developed in collaboration with Mayo Clinic, a shareholder of the Company.
2. Strategic partnership with Zimmer Biomet (NYSE:ZBH, ~$27B mkt cap) to exclusively commercialize and distribute EVO® diagnostic electrodes; accelerated payment of $3.5 million received in August 2022.
3. Potential to penetrate large disease populations including epilepsy, Parkinson’s disease, and spinal cord stimulation, with total addressable markets of $1+ billion, $5+ billion, and $10+ billion, respectively.
4. Multi-billion market opportunity for combination devices; potential for technology adaptation and entry into AI and machine learning markets.
5. Platform technology with licensing potential for applications in urinary incontinence, pain management, hypertension, depression, and other related neurological disorders.
6. Ample capital resources to support upcoming commercial and development catalysts including the commercial launch of the Evo sEEG diagnostic line, and further development of OneRF and a thin-film-based SCS electrode system.
Leadership with deep expertise in medical device technology, marketing, and business development; world-class board of directors; esteemed scientific and physician advisory boards.
_______________________________________________________________________________
$NMTC *** $NMTC *** $NMTC *** NMTC *** $NMTC *** $NMTC
NMTC Update
$NMTC
_____________________
Financial Highlights
Product revenue of $630,000 in Q3 2023, compared to $32,000 in Q3 2022
Collaboration revenue of $1.46 million in first nine months of FY 2023, compared to $6,000 in first nine months of FY 2022
Operating cash burn reduction expected with the completion of development of the OneRF™ Ablation System beginning in Fiscal Q4 2023.
__________________________________________________
$NMTC *** $NMTC *** $NMTC *** $NMTC
NMTC recent profile
________________________________
NMTC HAS NO DEBT OUTSTANDING AS OF JUNE 30, 2023
PRODUCT REVENUE OF $630,000 IN Q3 2023, COMPARED TO $32,000 IN Q3 2022
___________________________
$NMTC
EEENF's main accomplishment
_________________________________________________
88 Energy's announcement that they have completed their
'Small Share Holding Sale Facility' -- a way for EEENF to help
shareholders --the same shareholders who have seen their investment drastically dwindle 95% in value over the years due both to the company's relentless
dilution and perennial inability to find a drop of hydrocarbons-- have their company, 88 Energy, assist them in disposing their worthless positions for little or no cost.
A great service -- maybe the only one from this ticker -- so that shareholders will no longer have to
see their horrid EEENF positions in this company or recall how at one time they actually believed in it...
________________________________________________
....definitely not EEENF
Might come back some day.
AXXA share repurchase
$AXXA
__________________________
short interest: 224,000 shares (current shares short)
short interest as % of float: -- 0%::: shares available to borrow: 7,000,000
source: https://shortsqueeze.com/?symbol=axxa
_____________________________________
[compare with MU*LN:: short interest 36,280,000, % of float 18.9%.
_____________________________________________________
$AXXA *** $AXXA *** $AXXA
Last straw for Xalles
________________________________________________
Dangling 3 more acquisitions in front of us during that last
conference call while underhandedly plotting to increase
authorized shares 250% was shady.
Must think we're a bunch of hayseeds.
__________________________________________________________________
RTs offering by EEENF
Did anyone get charged for the 08/08/2023 88 Energy Ltd RTs offering by 88 Energy (Exp 08/22/2023), an offering from which USA holders were excluded from participating?
Schwab apparently gouged me for $80, calling it a 'service fee.'
Fee for what? - is what I'd like to know.
Thanks, gang!
error msg
Another pillage of shareholders
$EEENF
________________________________
Reaching over the banquet table and helping themselves to another 791,050,000 of our shares
that were not earned.
Haven't discovered a quart of oil in 5 years yet spent 10B shares to do just that, a trend that shows no sign of ending.
______________________________________________
There's more oil in this vintage can (and of higher quality) than has ever been found by this 20,000,000,000 share company of jackals.
Every PR they've issued has been negative. Rightly so as it turn out.
[img]http://i.ebayimg.com/images/g/KigAAOSw0Shgguyv/s-l1200.webp[image]
$AXXA descent cont'd
$AXXA
______________
Currently at $0.0022
$0.0001 above 5-year low of
$0.0021 on 10/29/2018.
Stock has lost 92% of its value since August 16, 2021 (or 2 yrs ago when it closed at $0.025) despite record earnings posted each quarter.
__________________________________________
$AXXA *** AXXA *** $AXXA *** AXXA *** AXXA